Sometimes, the best medicine for a stock is a simple dose of good news. On Tuesday, UnitedHealth Group Inc. (UNH) delivered just that, reporting first-quarter results that beat expectations and, more importantly, raising its profit outlook for the full year. Investors responded by sending the insurance giant's shares sharply higher.
The numbers tell a clear story. For the first quarter of 2026, UnitedHealth posted adjusted earnings of $7.23 per share. That wasn't just a beat—it was a blowout, sailing past the consensus estimate of $6.58. Revenue came in at $111.721 billion, up 2% year-over-year and also ahead of expectations.
But the real headline for anyone watching healthcare costs is the medical cost ratio. This metric, which shows what percentage of premium revenue is spent on medical care, came in at 83.9% for the quarter. That's down 90 basis points from the same period last year. In plain English, medical costs are easing as a portion of the business, which is exactly what investors and analysts want to see from a health insurer. It suggests the company is managing its core risk effectively.
The operating cost ratio did tick up to 13.8% from 12.4%, which the company says reflects investments in its people, processes, and technology. So, they're spending more to run the business, but they're spending less on actual medical claims. It's a trade-off that, so far, the market seems to like.
Digging into the segments, the core UnitedHealthcare insurance business saw revenue grow 2% to $86.3 billion. It served 49.1 million people and saw its operating margin expand. The Optum health services segment was a bit more mixed. Optum Health revenue dipped 3% to $24.1 billion, which the company attributed to having fewer value-based care members. However, across all its Optum businesses, the unit supported over 122 million consumers and generated $63.7 billion in revenue.
Beyond the quarterly numbers, UnitedHealth was busy on the strategic front. The company agreed to acquire Alegeus Technologies, a platform for administering consumer-directed healthcare accounts like HSAs and FSAs. The deal is expected to close later in 2026. At the same time, it completed the sale of its Optum UK business. The $400 million in net proceeds from that sale are headed to the United Health Foundation. And, in a move that directly rewards shareholders, the company entered into an arrangement to buy back at least $2 billion of its own stock, aiming to complete that by the end of the second quarter.
All of this activity feeds into a brighter outlook. UnitedHealth raised its fiscal 2026 adjusted earnings per share guidance. The new target is more than $18.25, up from the previous forecast of over $17.75. The consensus estimate had been sitting at $17.86, so the new guide is a meaningful step up. The company also bumped its GAAP earnings outlook to $17.35 per share from $17.10.
This confidence isn't happening in a vacuum. Earlier in April, the government gave the Medicare Advantage industry a welcome update. The Centers for Medicare & Medicaid Services (CMS) finalized payment rates for 2027 that are projected to increase payments to Medicare Advantage plans by 2.48%, or over $13 billion. That was better than some initial expectations and provided a tailwind for the entire sector, including UnitedHealth.
Put it all together—better-than-expected earnings, lower medical costs, strategic deals, a big buyback, and a raised outlook—and you get a stock on the move. According to market data, UnitedHealth shares were up 7.64% at $348.21 in premarket trading on Tuesday.
.jpeg)
